SOHO 2020

Immunotherapy for T-cell malignancies 7:38
Immunotherapy for T-cell malignancies
John DiPersio
Next questions in CAR-based therapies 3:56
Next questions in CAR-based therapies
John DiPersio
Innovative CAR designs 3:15
Innovative CAR designs
Renier J. Brentjens • 10 Sep 2020
Impact of COVID-19 on CAR T-cell therapies 4:27
Impact of COVID-19 on CAR T-cell therapies
David L. Porter • 17 Sep 2020
Challenges in CAR T-cell therapy 3:16
Challenges in CAR T-cell therapy
Renier J. Brentjens • 10 Sep 2020
Point-of-care CAR T-cells 1:11
Point-of-care CAR T-cells
Marcos de Lima • 16 Sep 2020
CAR-T therapy for aggressive B-cell lymphomas 2:42
CAR-T therapy for aggressive B-cell lymphomas
Peter A. Riedell • 2 Sep 2020
Anti-CD19 CAR T-cells for adults 4:51
Anti-CD19 CAR T-cells for adults
David L. Porter • 9 Sep 2020
State-of-the-art in CAR-T 2:54
State-of-the-art in CAR-T
Peter A. Riedell • 10 Sep 2020
Long-term outcomes of anti-CD19 CAR-T in R/R CLL 5:25
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
David L. Porter • 16 Sep 2020
Results of a site-manufactured anti-CD19 CAR-T in nHL 3:40
Results of a site-manufactured anti-CD19 CAR-T in nHL
Marcos de Lima • 24 Aug 2020
Outlook on the current CAR-T climate 5:18
Outlook on the current CAR-T climate
Marcos de Lima • 24 Aug 2020
The content of VJRegenMed is intended for healthcare professionals